Compare Amgen, Inc. (AMGN) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs J B Hunt Transport Services Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B). The key difference: Amgen, Inc. is far larger — about 9× J B Hunt Transport Services Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | JBHT | |
|---|---|---|
Market Cap | $224.14B | $24.92B |
Sector | Health | Industrials |
52-Week High | $417.20 | $298.41 |
52-Week Low | $271.18 | $130.65 |
Enterprise Value | $267.45B | $26.06B |
Dividend Yield | 2.43% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
JBHT trades at $275.86, up 3.65% today, with a bearish technical signal but strong analyst support. Recent quarters show earnings beats, with Q3 2026 expected at $2.12 EPS. Revenue is projected to grow to $12.7B in 2026, with a net income margin of 5.31%. The company maintains solid profitability metrics, including an 18.45% ROE, and announced a $0.45 dividend payable in August 2026.
The outlook is mixed; strong fundamentals and a $299.82 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. Investors should weigh earnings consistency against market volatility and sector headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
